New combo aims to stop leukemia return in High-Risk patients

NCT ID NCT05361057

Terminated Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether combining venetoclax with either azacytidine or a DA chemotherapy regimen could prevent relapse in acute myeloid leukemia patients who still have detectable cancer cells (MRD positive) after standard treatment. The trial planned to enroll 20 adults in complete remission but with high-risk MRD. Unfortunately, the study was terminated early, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Venetoclax combined with azacytidine or daunorubicin and cytarabine
What this could lead to: If successful, this approach could help prevent leukemia relapse in patients with persistent minimal residual disease who cannot undergo stem cell transplant.
What could go wrong: The trial was terminated early with only 20 participants, so results are limited. The combination drugs have significant side effects like low blood counts and infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA MEASURABLE DISEASE

Contacts and locations

Locations

HBDH

Tianjin, Tianjin Municipality, 300020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.